biotech · Relapsed/Refractory Large B Cell Lymphoma · Relapsed/Refractory Multiple Myeloma · ALLO
Allogene Therapeutics
Allogene Therapeutics patent portfolio — 16 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2017
- Employees
- 208
- Programs
- 8
- Drugs
- 2
- Patents
- 16
Allogene Therapeutics patents
16 pharmaceutical patents indexed for Allogene Therapeutics. 0 expire within 24 months.
Allogene Therapeutics has 16 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12404315
Protease-activating CD45-gate CAR
granted -
US 12365873
Methods for transducing immune cells
granted -
US 12295362
Formulations and processes for CAR T cell drug products
granted -
US 12221462
Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells
granted -
US 12215347
Chimeric antigen receptors with enhanced signaling and activities and uses thereof
granted -
US 12163153
Methods of manufacturing allogeneic CAR T cells
granted -
US 12163169
Inducible chimeric cytokine receptors
granted -
US 12104188
Modified caspase-9 polypeptides and methods of use thereof
granted -
US 12043655
Constitutively active chimeric cytokine receptors
granted -
US 12036243
BCMA CAR-T cells with enhanced activities
granted -
US 11896617
Polynucleotides encoding rituximab-resistant chimeric antigen receptors
granted -
US 11786553
Chimeric cytokine receptors bearing a PD-1 ectodomain
granted -
US 11732041
Antibodies against 4G7-derived chimeric antigen receptors
granted -
US 11673953
DLL3 targeting chimeric antigen receptors and binding agents
granted -
US 11326156
Modified caspase-9 polypeptides and methods of use thereof
granted -
US 11072644
Inhibitory chimeric antigen receptors
granted
Frequently asked questions
How many patents does Allogene Therapeutics have?
16 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Allogene Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.